---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-275406"
form_type: "8-K"
ticker: "MCRB"
cik: "0001609809"
company_name: "Seres Therapeutics, Inc."
filed_at: "2022-11-02T23:59:59+00:00"
generated_at: "2026-06-22T14:05:00.376343+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Seres reports Q3 2022 net loss $60M; SER-109 BLA accepted for Priority Review with PDUFA April 26, 2023

## Summary
- Net loss of $60.0M in Q3 2022 vs net income of $68.2M in Q3 2021; R&D expenses $43.1M.
- FDA accepted SER-109 BLA for Priority Review; PDUFA target action date April 26, 2023.
- ECOSPOR IV open-label study: 91.3% of patients achieved sustained clinical response at 8 weeks.
- Cash, cash equivalents and marketable securities $233.0M as of Sept 30, 2022.
- SER-155 cohort 1 enrollment complete; DSMB safety review by year end; initial data early 2023.

## SEC filing metadata
- accession: 0001193125-22-275406
- form_type: 8-K
- ticker: MCRB
- cik: 0001609809
- company_name: Seres Therapeutics, Inc.
- filed_at: 2022-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1609809/000119312522275406/0001193125-22-275406-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1609809/000119312522275406/d377816d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-275406
- JSON: https://secwatch.observer/filing/0001193125-22-275406.json
- Plain text: https://secwatch.observer/filing/0001193125-22-275406.txt

## Key facts
- Earnings Releases
  Seres Therapeutics, Inc. reported financial results for third quarter 2022.
  - Period: third quarter 2022
  - Result: reported results
  source text: Seres Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2022 and provided operational updates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1609809/000119312522275406/0001193125-22-275406-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.